<DOC>
	<DOCNO>NCT00181155</DOCNO>
	<brief_summary>This study test hypothesis allopurinol , xanthine oxidase inhibitor , improve heart metabolism patient heart failure .</brief_summary>
	<brief_title>Intravenous Allopurinol Heart Failure</brief_title>
	<detailed_description>Xanthine oxidase report improve mechano-energetic coupling fail heart . The investigator develop mean directly measure creatine kinase flux , major energy reserve heart , human heart exploit new magnetic resonance technology . The investigator propose study 10 healthy subject 25 heart failure ( dilate cardiomyopathy ) single 300mg IV infusion allopurinol .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Allopurinol</mesh_term>
	<criteria>1 . Age &gt; 18 year 2 . The patient willing able provide inform consent 3 . Clinical diagnosis chronic heart failure 4 . Ejection fraction ( EF ) &lt; 40 % echocardiography , nuclear multigated acquisition ( MUGA ) cath ventriculography 5 . No significant coronary disease cardiac catheterization 6 . New York Heart Association ( NYHA ) Class IIV symptoms 7 . Clinical stabilization two week follow recent congestive heart failure ( CHF ) decompensation . 1 . Metallic implant prohibit magnetic resonance ( MR ) evaluation 2 . Inability lie flat MR study 3 . Administration additional investigational drug 4 . Calculated creatinine clearance &lt; 50 mL/min 5 . Allergy allopurinol 6 . Current gout flare 7 . Currently take oral allopurinol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>metabolism</keyword>
	<keyword>congestive heart failure</keyword>
	<keyword>allopurinol</keyword>
	<keyword>Adenosine triphosphate ( ATP )</keyword>
</DOC>